Welcome to our dedicated page for Hoth Therapeutics SEC filings (Ticker: HOTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hoth Therapeutics, Inc. (HOTH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company, Hoth uses forms such as 10-K, 10-Q, 8-K, and registration statements to report on its business, financial condition, and material events.
In its Form 8-K filings, Hoth has reported items such as corporate presentations, employment agreements with key executives, patent-related developments for HT-001, and listing-compliance matters with The Nasdaq Capital Market. These current reports can give investors insight into topics like executive compensation arrangements, intellectual property strategy, and communications the company uses in discussions with investors.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically include detailed descriptions of Hoth’s pipeline programs, risk factors, research and development expenses, and other information relevant to its operations as a clinical-stage biopharmaceutical company. For Hoth, this may encompass narrative and disclosures related to HT-001, HT-KIT, HT-ALZ, its GDNF-based metabolic program, and other assets described in its public communications.
Stock Titan enhances access to these filings with AI-powered summaries that are designed to highlight key points from lengthy documents, such as major pipeline updates, regulatory milestones, or changes in capital structure. Users can review real-time updates as new filings are posted to EDGAR, explore Form 4 insider transaction reports when filed, and quickly navigate to sections that discuss clinical development, intellectual property, and corporate governance.
By using this page, investors and researchers can examine HOTH’s SEC filings alongside AI-generated explanations that aim to clarify complex language and help identify significant disclosures without replacing the need to read the original documents.
Robb Knie, CEO and President and a director of Hoth Therapeutics, acquired 800,000 shares of restricted common stock under the company’s Amended and Restated 2022 Equity Incentive Plan; the award vested in full at grant and was issued at $0 per share, bringing his post-award beneficial ownership to 858,131 shares. The next day he sold 310,744 shares at $1.21 per share, reducing his beneficial ownership to 547,387 shares. The Form 4 shows the acquisition was labeled as an issuance that vested on grant and the sale was reported separately. The filing was signed by an attorney-in-fact on behalf of Mr. Knie.
Hoth Therapeutics, Inc. disclosed a material agreement: an Employment Agreement between the company and Robb Knie dated August 22, 2025. The filing is an Form 8-K reporting that the employment contract was furnished as an exhibit and the document is signed by Robb Knie in his capacity as Chief Executive Officer. No financial terms, termination provisions, equity awards, or other compensation details appear in the provided text, and there are no financial statements or earnings information included.
Hoth Therapeutics, Inc. reported $9.0 million in cash and cash equivalents at June 30, 2025, up from $7.0 million at year-end 2024, and total assets of $10.1 million. The company recorded a six-month net loss of $5.68 million versus $3.86 million in the prior-year period, driven in part by a $1.25 million immediate expensing of acquired patent applications and higher research and development spending. Weighted average shares increased materially, lowering six-month loss per share to $0.44 from $0.68 a year earlier despite a larger absolute loss.
Operating cash used was $5.16 million for the six months, while financing activities provided $7.13 million, including $5.625 million from warrant exercises. Management states current cash is sufficient to fund operations for at least 12 months from issuance, but additional capital will be required for longer-term development and regulatory plans. The company continues clinical and preclinical programs across multiple candidates and maintains an ATM facility with selling capacity expanded to $7.7 million.
Hoth Therapeutics has filed an 8-K report announcing the preparation of new presentation materials that management plans to use for company presentations starting June 24, 2025. The materials are included as Exhibit 99.1 to the Current Report.
Key points from the filing:
- The presentation materials contain summary information that should be considered alongside the company's SEC filings and other public announcements
- The company maintains discretion to update the materials but has no obligation to do so
- Information provided under Item 7.01 and Exhibit 99.1 is furnished rather than "filed" under SEC regulations
- The information will not be incorporated by reference into any Securities Act or Exchange Act filings
The filing was signed by CEO Robb Knie and includes the standard Cover Page Interactive Data File in Inline XBRL format.
Hoth Therapeutics, Inc. ("HOTH") reported that, on June 18, 2025, The Nasdaq Stock Market notified the company that its common stock satisfied the minimum bid price requirement of $1.00 per share for at least ten consecutive business days, thereby restoring full compliance with Nasdaq Listing Rule 5550(a)(2). The company disclosed the notification in this Form 8-K and simultaneously issued a press release, furnished as Exhibit 99.1.